Literature DB >> 22106435

A comparative case study of bowel cancer screening in the UK and Australia: evidence lost in translation?

K L Flitcroft1, D J B St John, K Howard, S M Carter, M P Pignone, G P Salkeld, L J Trevena.   

Abstract

OBJECTIVES: (i) To document the current state of the English, Scottish, Welsh, Northern Irish and Australian bowel cancer screening programmes, according to seven key characteristics, and (ii) to explore the policy trade-offs resulting from inadequate funding.
SETTING: United Kingdom and Australia.
METHODS: A comparative case study design using document and key informant interview analysis. Data were collated for each national jurisdiction on seven key programme characteristics: screening frequency, population coverage, quality of test, programme model, quality of follow-up, quality of colonoscopy and quality of data collection. A list of optimal features for each of the seven characteristics was compiled, based on the FOBT screening literature and our detailed examination of each programme.
RESULTS: Each country made different implementation choices or trade-offs intended to conserve costs and/or manage limited and expensive resources. The overall outcome of these trade-offs was probable lower programme effectiveness as a result of compromises such as reduced screening frequency, restricted target age range, the use of less accurate tests, the deliberate setting of low programme positivity rates or increased inconvenience to participants from re-testing.
CONCLUSIONS: Insufficient funding has forced programme administrators to make trade-offs that may undermine the potential net population benefits achieved in randomized controlled trials. Such policy compromise contravenes the principle of evidence-based practice which is dependent on adequate funding being made available.

Entities:  

Mesh:

Year:  2011        PMID: 22106435      PMCID: PMC3466604          DOI: 10.1258/jms.2011.011066

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  17 in total

1.  The effect of fecal occult-blood screening on the incidence of colorectal cancer.

Authors:  J S Mandel; T R Church; J H Bond; F Ederer; M S Geisser; S J Mongin; D C Snover; L M Schuman
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 2.  Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

Authors:  P Hewitson; P Glasziou; L Irwig; B Towler; E Watson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.

Authors:  L Guittet; V Bouvier; N Mariotte; J P Vallee; D Arsène; S Boutreux; J Tichet; G Launoy
Journal:  Gut       Date:  2006-08-04       Impact factor: 23.059

4.  Option appraisal of population-based colorectal cancer screening programmes in England.

Authors:  Paul Tappenden; James Chilcott; Simon Eggington; Julietta Patnick; Hannah Sakai; Jonathon Karnon
Journal:  Gut       Date:  2006-12-01       Impact factor: 23.059

5.  Optimal dietary conditions for hemoccult testing.

Authors:  F A Macrae; D J St John; P Caligiore; L S Taylor; J W Legge
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

6.  Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.

Authors:  Michael P Pignone; Kathy L Flitcroft; Kirsten Howard; Lyndal J Trevena; Glenn P Salkeld; D James B St John
Journal:  Med J Aust       Date:  2011-02-21       Impact factor: 7.738

7.  High participation rates are not necessary for cost-effective colorectal cancer screening.

Authors:  Kirsten Howard; Glenn Salkeld; Les Irwig; Barbara-Ann Adelstein
Journal:  J Med Screen       Date:  2005       Impact factor: 2.136

8.  Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population.

Authors:  Guy D Launoy; Hughes J Bertrand; Celia Berchi; Vincent Y Talbourdet; Anne Valérie N Guizard; Véronique M Bouvier; Emile R Caces
Journal:  Int J Cancer       Date:  2005-06-20       Impact factor: 7.396

9.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

10.  Colorectal cancer screening: a comparison of 35 initiatives in 17 countries.

Authors:  Victoria S Benson; Julietta Patnick; Anna K Davies; Marion R Nadel; Robert A Smith; Wendy S Atkin
Journal:  Int J Cancer       Date:  2008-03-15       Impact factor: 7.396

View more
  4 in total

1.  Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia.

Authors:  Alison Brenner; Kirsten Howard; Carmen Lewis; Stacey Sheridan; Trisha Crutchfield; Sarah Hawley; Dan Reuland; Christine Kistler; Michael Pignone
Journal:  J Gen Intern Med       Date:  2013-11-23       Impact factor: 5.128

Review 2.  Colorectal cancer screening: why immunochemical fecal occult blood tests may be the best option.

Authors:  Kathy L Flitcroft; Les M Irwig; Stacy M Carter; Glenn P Salkeld; James A Gillespie
Journal:  BMC Gastroenterol       Date:  2012-12-29       Impact factor: 3.067

3.  Impact of faecal haemoglobin concentration on colorectal cancer mortality and all-cause death.

Authors:  Li-Sheng Chen; Amy Ming-Fang Yen; Callum G Fraser; Sherry Yueh-Hsia Chiu; Jean Ching-Yuan Fann; Po-En Wang; Sheng-Che Lin; Chao-Sheng Liao; Yi-Chia Lee; Han-Mo Chiu; Hsiu-Hsi Chen
Journal:  BMJ Open       Date:  2013-11-07       Impact factor: 2.692

4.  Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy.

Authors:  Michael G Collins; Edward Teo; Stephen R Cole; Choy-Yoke Chan; Stephen P McDonald; Graeme R Russ; Graeme P Young; Peter A Bampton; P Toby Coates
Journal:  BMJ       Date:  2012-07-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.